First-week increases in activated peripheral B-cell subset frequencies are associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab

Background Although immune checkpoint inhibitors (ICIs) cause grade 3 or higher immune-related adverse events (irAEs), validated biomarkers for identifying patients at risk of these events are lacking. Given the potential contribution of B-cells to irAE development, we evaluated whether early changes in circulating B-cell subsets after nivolumab plus ipilimumab were associated with subsequent severe irAEs. Materials and methods This prospective observational study included 12 patients who received nivolumab plus ipilimumab, and an exploratory cohort of five patients who received anti-PD-1 monotherapy. Blood was sampled before treatment, at week 1, and before cycle 2. Flow cytometry quantified CD21 low B-cells, CD27 + IgD − class-switched B-cells, plasmablasts, and CD19 + CD138 + plasma cells. irAEs were assessed for 6 months, and fold changes at week 1 were compared between patients with and without severe irAEs. Paired immunoglobulin G B-cell receptor (BCR) repertoires were analyzed in four patients with grade 3 or higher irAEs. One patient developed myasthenia gravis, and anti-acetylcholine receptor (AChR) antibody was measured in serial serum samples. Results In the nivolumab plus ipilimumab patients, grade 3 or higher irAEs occurred in five patients. Week-1 frequency fold changes in all four activated B-cell subsets were significantly greater in these patients, whereas total CD19 + B-cell changes did not differ. Rarefied IgG BCR diversity generally increased in repertoires derived from peripheral blood mononuclear cells, while Gini coefficients decreased in all paired repertoires. In the myasthenia gravis case, anti-AChR antibody exceeded the reference range by Day 11, before symptoms and diagnosis. Conclusion First-week increases in activated peripheral B-cell subset frequencies after nivolumab plus ipilimumab were associated with subsequent severe irAEs. These findings support future studies of early B-cell monitoring within integrated multimarker assessments of irAE risk.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1991299
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

First-week increases in activated peripheral B-cell subset frequencies are associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab

Yumiko Inui, Jae Man Lee, Naomi Kiyota, Shiro Kimbara et al.
1 links
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

First-week increases in activated peripheral B-cell subset frequencies are associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab

Yumiko Inui, Jae Man Lee, Naomi Kiyota, Shiro Kimbara, Kimikazu Yakushijin, Eriko Fukuda, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Yohei Funakoshi, Hidetomo Takakura, Hironobu Minami, Tomoki Sasaki
article en

Abstract

Background Although immune checkpoint inhibitors (ICIs) cause grade 3 or higher immune-related adverse events (irAEs), validated biomarkers for identifying patients at risk of these events are lacking. Given the potential contribution of B-cells to irAE development, we evaluated whether early changes in circulating B-cell subsets after nivolumab plus ipilimumab were associated with subsequent severe irAEs. Materials and methods This prospective observational study included 12 patients who received nivolumab plus ipilimumab, and an exploratory cohort of five patients who received anti-PD-1 monotherapy. Blood was sampled before treatment, at week 1, and before cycle 2. Flow cytometry quantified CD21 low B-cells, CD27 + IgD − class-switched B-cells, plasmablasts, and CD19 + CD138 + plasma cells. irAEs were assessed for 6 months, and fold changes at week 1 were compared between patients with and without severe irAEs. Paired immunoglobulin G B-cell receptor (BCR) repertoires were analyzed in four patients with grade 3 or higher irAEs. One patient developed myasthenia gravis, and anti-acetylcholine receptor (AChR) antibody was measured in serial serum samples. Results In the nivolumab plus ipilimumab patients, grade 3 or higher irAEs occurred in five patients. Week-1 frequency fold changes in all four activated B-cell subsets were significantly greater in these patients, whereas total CD19 + B-cell changes did not differ. Rarefied IgG BCR diversity generally increased in repertoires derived from peripheral blood mononuclear cells, while Gini coefficients decreased in all paired repertoires. In the myasthenia gravis case, anti-AChR antibody exceeded the reference range by Day 11, before symptoms and diagnosis. Conclusion First-week increases in activated peripheral B-cell subset frequencies after nivolumab plus ipilimumab were associated with subsequent severe irAEs. These findings support future studies of early B-cell monitoring within integrated multimarker assessments of irAE risk.

Frontiers in ImmunologyVol. 17
Kyushu University (JP), Kobe University Hospital (JP), Fukuoka City Hospital (JP), Cellular and Molecular Biotechnology Research Institute (JP), Kobe University (JP), National Institute of Advanced Industrial Science and Technology (JP)
Japan Society for the Promotion of Science
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon